Table 3 Best overall response.

From: PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer

Best overall response

FOLFIRI and AZD8931

AZD 20 mg bd

AZD 40 mg bd

AZD 80 mg bd

AZD 160 mg bd

N = 2

N = 2

N = 2

N = 12

N (%)

N (%)

N (%)

N (%)

Partial response

1 (50%)

1 (50%)

1 (50%)

3 (25%)

Stable disease

–

1 (50%)

–

8 (67%)

Progressive disease

1 (50%)

–

–

1 (8%)

Not assessed

–

–

1 (50%)a

–

  1. aPatient died prior to 12-week scan.
Back to article page